SABS logo

SAB Biotherapeutics (SABS) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 February 2021

Indexes:

Not included

Description:

SAB Biotherapeutics is a biotechnology company focused on developing innovative therapies using its unique platform for producing fully human polyclonal antibodies. Their approach aims to treat various diseases, including autoimmune disorders and infectious diseases, by harnessing the power of the immune system for effective treatments.

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Mar 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 05, 2024

Analyst ratings

Recent major analysts updates

07 Nov '24 Chardan Capital
Buy
09 Oct '24 Craig-Hallum
Buy
12 Sept '24 Oppenheimer
Outperform
09 Sept '24 Chardan Capital
Buy
28 Aug '24 Oppenheimer
Outperform
12 Aug '24 HC Wainwright & Co.
Buy
12 Aug '24 Chardan Capital
Buy
07 June '24 Brookline Capital
Buy
21 May '24 HC Wainwright & Co.
Buy
21 May '24 Chardan Capital
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SABS
GlobeNewsWire08 April 2024

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.

Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now
SABS
Zacks Investment Research08 December 2023

SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic
SABS
Proactive Investors13 April 2023

SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.

FAQ

  • What is the primary business of SAB Biotherapeutics?
  • What is the ticker symbol for SAB Biotherapeutics?
  • Does SAB Biotherapeutics pay dividends?
  • What sector is SAB Biotherapeutics in?
  • What industry is SAB Biotherapeutics in?
  • What country is SAB Biotherapeutics based in?
  • When did SAB Biotherapeutics go public?
  • Is SAB Biotherapeutics in the S&P 500?
  • Is SAB Biotherapeutics in the NASDAQ 100?
  • Is SAB Biotherapeutics in the Dow Jones?
  • When was SAB Biotherapeutics's last earnings report?
  • When does SAB Biotherapeutics report earnings?
  • Should I buy SAB Biotherapeutics stock now?

What is the primary business of SAB Biotherapeutics?

SAB Biotherapeutics is a biotechnology company focused on developing innovative therapies using its unique platform for producing fully human polyclonal antibodies. Their approach aims to treat various diseases, including autoimmune disorders and infectious diseases, by harnessing the power of the immune system for effective treatments.

What is the ticker symbol for SAB Biotherapeutics?

The ticker symbol for SAB Biotherapeutics is NASDAQ:SABS

Does SAB Biotherapeutics pay dividends?

No, SAB Biotherapeutics does not pay dividends

What sector is SAB Biotherapeutics in?

SAB Biotherapeutics is in the Healthcare sector

What industry is SAB Biotherapeutics in?

SAB Biotherapeutics is in the Biotechnology industry

What country is SAB Biotherapeutics based in?

SAB Biotherapeutics is headquartered in United States

When did SAB Biotherapeutics go public?

SAB Biotherapeutics's initial public offering (IPO) was on 09 February 2021

Is SAB Biotherapeutics in the S&P 500?

No, SAB Biotherapeutics is not included in the S&P 500 index

Is SAB Biotherapeutics in the NASDAQ 100?

No, SAB Biotherapeutics is not included in the NASDAQ 100 index

Is SAB Biotherapeutics in the Dow Jones?

No, SAB Biotherapeutics is not included in the Dow Jones index

When was SAB Biotherapeutics's last earnings report?

SAB Biotherapeutics's most recent earnings report was on 6 November 2024

When does SAB Biotherapeutics report earnings?

The next expected earnings date for SAB Biotherapeutics is 28 March 2025

Should I buy SAB Biotherapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions